October 2010 Briefing - HIV & AIDS
Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for October 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Primary Care Trails Other Specialties in Hourly Wages
TUESDAY, Oct. 26 (HealthDay News) -- Primary care physicians have substantially lower hourly wages than other specialists, and although most physicians find Medicare reimbursement inequitable, they show little consensus on how to reform it, according to two studies published in the Oct. 25 issue of the Archives of Internal Medicine.
HIV Drug Invirase Gets New Label Reflecting Risk
THURSDAY, Oct. 21 (HealthDay News) -- New risk information has been added to the label of the HIV antiviral drug Invirase (saquinavir), notifying patients and health care professionals that the drug can have potentially life-threatening adverse effects when used in combination with another antiviral drug, according to an announcement by the U.S. Food and Drug Administration.
Studies Assess Regimens After Nevirapine
WEDNESDAY, Oct. 13 (HealthDay News) -- In women with HIV-1 who have taken peripartum single-dose nevirapine, the use of ritonavir-boosted lopinavir with tenofovir-emtricitabine is associated with better outcomes than therapy featuring nevirapine, and in children with prior nevirapine exposure, benefits are seen with zidovudine and lamivudine plus ritonavir-boosted lopinavir, according to two studies published in the Oct. 14 issue of The New England Journal of Medicine.
Age at Cancer Diagnosis Similar in AIDS, General Populations
TUESDAY, Oct. 5 (HealthDay News) -- After adjustment for the lower proportion of older-age patients among the AIDS population, most cancers in this population are diagnosed at an age similar to that in the general population, according to research published in the Oct. 5 issue of the Annals of Internal Medicine.